Bioverativ Therapeutics Overview
- Status
-
Acquired/Merged
- Employees
-
500
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
- Investments
-
2
Bioverativ Therapeutics General Information
Description
Provider of biotechnology services intended to address various issues related to the treatment of chronic blood disorders. The company's biotechnology services include offering therapies, clinical trials, research and development of treatment methods for the treatment of cold agglutinin disease, sickle cell disease and beta-thalassemia, enabling medical institutions and patients to get a wide range of scientific treatments to fight fatal blood diseases.
Contact Information
Website
www.bioverativ.comCorporate Office
- 225 Second Avenue
- Waltham, MA 02451
- United States
Corporate Office
- 225 Second Avenue
- Waltham, MA 02451
- United States
Bioverativ Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bioverativ Therapeutics Comparisons
Industry
Financing
Details
Bioverativ Therapeutics Competitors (15)
One of Bioverativ Therapeutics’s 15 competitors is Biogen, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Inventiva Pharma | Corporation | Daix, France | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India |
Bioverativ Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bioverativ Therapeutics Patents
Bioverativ Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023320363-A1 | Methods for treating hemophilia a and population pharmacokinetics tools for determining treatments and uses thereof | Pending | 01-Aug-2022 | ||
| EP-4489771-A2 | Methods of treating hemophilia a | Pending | 08-Mar-2022 | ||
| US-20250092117-A1 | Methods of treating hemophilia a | Pending | 08-Mar-2022 | ||
| AU-2023230889-A1 | Methods of treating hemophilia a | Pending | 08-Mar-2022 | ||
| US-20240294940-A1 | Baculovirus expression system | Pending | 14-Feb-2022 | C12N15/86 |
Bioverativ Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bioverativ Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bioverativ Therapeutics Investments & Acquisitions (2)
Bioverativ Therapeutics’s most recent deal was a Corporate Asset Purchase with Amunix (Royalties). The deal was made on 01-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amunix (Royalties) | 01-Jan-2018 | Corporate Asset Purchase | Buildings and Property | ||
| True North Therapeutics | 28-Jun-2017 | Merger/Acquisition | Drug Discovery |
Bioverativ Therapeutics FAQs
-
Where is Bioverativ Therapeutics headquartered?
Bioverativ Therapeutics is headquartered in Waltham, MA.
-
What is the size of Bioverativ Therapeutics?
Bioverativ Therapeutics has 500 total employees.
-
What industry is Bioverativ Therapeutics in?
Bioverativ Therapeutics’s primary industry is Biotechnology.
-
Is Bioverativ Therapeutics a private or public company?
Bioverativ Therapeutics is a Private company.
-
What is the current valuation of Bioverativ Therapeutics?
The current valuation of Bioverativ Therapeutics is .
-
What is Bioverativ Therapeutics’s current revenue?
The current revenue for Bioverativ Therapeutics is .
-
Who are Bioverativ Therapeutics’s investors?
Biogen, Fidelity Equity Partners (Massachusetts), Jennison Associates, and ValueAct Capital Management have invested in Bioverativ Therapeutics.
-
Who are Bioverativ Therapeutics’s competitors?
Biogen, Inventiva Pharma, Novavax, Astellas Pharma, and Biocon are some of the 15 competitors of Bioverativ Therapeutics.
-
When was Bioverativ Therapeutics acquired?
Bioverativ Therapeutics was acquired on 08-Mar-2018.
-
Who acquired Bioverativ Therapeutics?
Bioverativ Therapeutics was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
